Published in Mol Cell Biol on November 01, 1996
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 2.41
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer (2009) 1.79
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol (1997) 1.57
PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A (2000) 1.55
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis (2008) 1.33
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer (2002) 1.29
The transcription factor p53: not a repressor, solely an activator. Cell Cycle (2014) 1.23
Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol (2005) 1.15
Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer (2009) 1.09
The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci (2013) 1.07
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis (2013) 1.01
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene (2010) 0.99
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev (2015) 0.96
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol (2014) 0.95
Role of p53 in Cell Death and Human Cancers. Cancers (Basel) (2011) 0.95
Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene (2008) 0.90
TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol (2011) 0.88
Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget (2016) 0.85
TP53 mutation, mitochondria and cancer. Curr Opin Genet Dev (2016) 0.84
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys (2011) 0.84
Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck (2012) 0.83
Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion. Reprod Biol Endocrinol (2009) 0.83
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor. Br J Cancer (1999) 0.80
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget (2016) 0.79
Whole genome expression profiling shows that BRG1 transcriptionally regulates UV inducible genes and other novel targets in human cells. PLoS One (2014) 0.78
Expression of p53 target genes in the early phase of long-term potentiation in the rat hippocampal CA1 area. Neural Plast (2015) 0.77
PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene (2009) 0.76
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci (2016) 0.75
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells. Oncotarget (2016) 0.75
ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin. Nat Commun (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
p53 mutations in human cancers. Science (1991) 31.96
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
How eukaryotic transcriptional activators work. Nature (1988) 19.34
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
The locus of sequence-directed and protein-induced DNA bending. Nature (1984) 15.05
The p53 tumour suppressor gene. Nature (1991) 14.49
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
A new class of yeast transcriptional activators. Cell (1987) 9.53
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
p53 function and dysfunction. Cell (1992) 7.73
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 7.24
Empirical estimation of protein-induced DNA bending angles: applications to lambda site-specific recombination complexes. Nucleic Acids Res (1988) 7.05
Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J (1994) 6.83
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell (1991) 6.04
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev (1993) 6.02
Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell (1993) 5.91
Activators and targets. Nature (1990) 5.89
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Transcriptional repression of eukaryotic promoters. Cell (1989) 5.60
Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem (1987) 5.57
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Epidermal growth factor. J Biol Chem (1990) 4.79
Binding of general transcription factor TFIIB to an acidic activating region. Nature (1991) 4.71
Bending of DNA by gene-regulatory proteins: construction and use of a DNA bending vector. Gene (1989) 4.41
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Signalling by receptor tyrosine kinases. Annu Rev Biochem (1993) 4.11
Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A (1985) 4.08
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev (1993) 3.99
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science (1995) 3.74
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (1996) 3.70
Structural aspects of the p53 protein in relation to gene evolution. Oncogene (1990) 3.64
Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (1995) 3.55
Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol (1994) 3.46
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
The tumor suppressor genes. Annu Rev Biochem (1993) 3.12
Fos-Jun heterodimers and Jun homodimers bend DNA in opposite orientations: implications for transcription factor cooperativity. Cell (1991) 3.09
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A (1991) 2.86
DNA bending and orientation-dependent function of YY1 in the c-fos promoter. Genes Dev (1993) 2.80
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76
p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev (1993) 2.74
The tumor suppressor p53. Biochim Biophys Acta (1993) 2.65
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol (1993) 2.37
Involvement of growth factor receptors in the mammalian UVC response. Cell (1994) 2.28
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem (1993) 2.15
Action at a distance along a DNA. Science (1988) 2.13
Selective DNA bending by a variety of bZIP proteins. Mol Cell Biol (1993) 2.12
A potential transcriptional activation element in the p53 protein. Oncogene (1990) 2.07
Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell (1994) 2.06
Regulation of the human hsp70 promoter by p53. Science (1993) 2.02
Promoter-selective transcriptional defect in cell cycle mutant ts13 rescued by hTAFII250. Science (1994) 2.02
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene (1994) 2.01
The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A (1993) 2.01
Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell (1989) 2.00
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene (1993) 1.77
Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol (1995) 1.76
Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol (1995) 1.73
Transcriptional activation by simian virus 40 large T antigen: interactions with multiple components of the transcription complex. Mol Cell Biol (1993) 1.73
Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci U S A (1994) 1.69
Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys (1994) 1.67
Phosphorylation of the erythroid transcription factor GATA-1. J Biol Chem (1994) 1.65
Why bend DNA? Cell (1990) 1.64
How loops, beta sheets, and alpha helices help us to understand p53. Cell (1994) 1.60
The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res (1988) 1.58
Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene (1995) 1.52
Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation. Genes Dev (1993) 1.45
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
p53 binds to the TATA-binding protein-TATA complex. J Biol Chem (1993) 1.42
Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc Natl Acad Sci U S A (1995) 1.42
Role of epidermal growth factor in carcinogenesis. Cancer Res (1986) 1.41
The p53 tumor suppressor protein: meeting review. Genes Dev (1993) 1.41
Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites. J Biol Chem (1988) 1.35
Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J (1995) 1.34
Myc/Max and other helix-loop-helix/leucine zipper proteins bend DNA toward the minor groove. Proc Natl Acad Sci U S A (1992) 1.30
Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem (1993) 1.27
Opposite orientations of DNA bending by c-Myc and Max. Proc Natl Acad Sci U S A (1992) 1.27
Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem (1988) 1.25
p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem (1995) 1.20
Differential ability of proximal and remote element pairs to cooperate in activating RNA polymerase II transcription. Mol Cell Biol (1991) 1.18
Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res (1995) 1.16
Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene (1994) 1.16
Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci U S A (1996) 1.15
p53 and human cancers. Br Med Bull (1994) 1.11
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Helper T cell differentiation is controlled by the cell cycle. Immunity (1998) 5.71
Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A (2000) 3.24
Functional interactions of the simian virus 40 core origin of replication with flanking regulatory sequences. J Virol (1986) 3.15
Trehalose expression confers desiccation tolerance on human cells. Nat Biotechnol (2000) 2.98
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1998) 2.92
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med (1997) 2.81
Patterns and correlates of physical activity among US women 40 years and older. Am J Public Health (2000) 2.79
Domain structure of the simian virus 40 core origin of replication. Mol Cell Biol (1986) 2.72
Promoting physical activity in rural communities: walking trail access, use, and effects. Am J Prev Med (2000) 2.65
Psychological monitoring of overtraining and staleness. Br J Sports Med (1987) 2.33
The adenine-thymine domain of the simian virus 40 core origin directs DNA bending and coordinately regulates DNA replication. Mol Cell Biol (1986) 2.31
The T-antigen-binding domain of the simian virus 40 core origin of replication. J Virol (1987) 2.08
Reliability of information on physical activity and other chronic disease risk factors among US women aged 40 years or older. Am J Epidemiol (1999) 1.97
Replacement of bovine mitochondrial DNA by a sequence variant within one generation. Genetics (1991) 1.96
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene (2011) 1.95
Simian virus 40 large tumor antigen requires three core replication origin domains for DNA unwinding and replication in vitro. Proc Natl Acad Sci U S A (1987) 1.89
Complex structure and regulation of the P16 (MTS1) locus. Cancer Res (1995) 1.87
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
Cloning of the filamentous hemagglutinin of Bordetella pertussis and its expression in Escherichia coli. Infect Immun (1987) 1.69
Identification of a chromosomal determinant of alpha-toxin production in Staphylococcus aureus. Infect Immun (1980) 1.65
Intraoperative ventilator settings and acute lung injury after elective surgery: a nested case control study. Thorax (2008) 1.64
Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron (1998) 1.64
Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun (1995) 1.61
Breath hydrogen excretion as a screening test for the early diagnosis of necrotizing enterocolitis. Am J Dis Child (1989) 1.58
Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Res (1998) 1.55
Impact on process of trauma care delivery 1 year after the introduction of a trauma program in a provincial trauma center. J Trauma (1999) 1.52
Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol (1999) 1.51
An improved in vitro pyrogen test: to detect picograms of endotoxin contamination in intravenous fluids using limulus amoebocyte lysate. J Lab Clin Med (1977) 1.50
Role of microglia in neuronal cell death in prion disease. Brain Pathol (1998) 1.49
A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res (1999) 1.46
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
Hand-held portable sonography for the on-mountain exclusion of a pneumothorax. Wilderness Environ Med (2001) 1.43
Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei). Vet Pathol (2000) 1.43
Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 1.43
p53 binds to the TATA-binding protein-TATA complex. J Biol Chem (1993) 1.42
Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene (2007) 1.41
Analysis of bacteriophage phi X174 gene A protein-mediated termination and reinitiation of phi X DNA synthesis. II. Structural characterization of the covalent phi X A protein-DNA complex. J Biol Chem (1984) 1.41
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics (1996) 1.41
A multicomponent program for nutrition and physical activity change in primary care: PACE+ for adolescents. Arch Pediatr Adolesc Med (2001) 1.40
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A (2001) 1.39
The superiority of combined therapy (surgery and postoperative irradiation) in parotid cancer. Arch Otolaryngol (1982) 1.38
Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis (1999) 1.38
Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis (2000) 1.38
Cephalexin-supplemented Jones-Kendrick charcoal agar for selective isolation of Bordetella pertussis: comparison with previously described media. J Clin Microbiol (1983) 1.37
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
Aberrant metal binding by prion protein in human prion disease. J Neurochem (2001) 1.33
Integration of antagonistic signals in the regulation of nitrogen assimilation in Escherichia coli. Curr Top Cell Regul (2000) 1.32
Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology (2000) 1.31
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem (2001) 1.30
Perceived barriers to exercise and stage of exercise adoption in older women of different racial/ethnic groups. Women Health (2000) 1.28
The Escherichia coli PII signal transduction protein regulates the activities of the two-component system transmitter protein NRII by direct interaction with the kinase domain of the transmitter module. Biochemistry (2000) 1.28
The use of quaternary narcotic antagonists in opiate research. Neuropharmacology (1985) 1.27
The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J (1998) 1.26
Support for policy interventions to increase physical activity in rural Missouri. Am J Health Promot (1998) 1.26
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med (1985) 1.26
Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors. Proc Natl Acad Sci U S A (2001) 1.26
The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci U S A (1993) 1.26
Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol (2007) 1.23
Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J Clin Microbiol (1999) 1.22
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis (1997) 1.20
Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation (1997) 1.20
Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol (2001) 1.20
28-day survival rates of 6676 neonates with birth weights of 1250 grams or less. Pediatrics (1991) 1.19
Optimization of benzoyl peroxide concentration in an experimental bone cement based on poly(methyl methacrylate). J Mater Sci Mater Med (1997) 1.19
'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene (1998) 1.17
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol (1997) 1.17
Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene (1994) 1.16
Screening for lead poisoning in an urban pediatric clinic using samples obtained by fingerstick. Pediatrics (1994) 1.15
Suppression of p53 activity by Siva1. Cell Death Differ (2009) 1.14
Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene (2000) 1.14
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol (1998) 1.14
The hamster model of intraperitoneal Burkholderia mallei (glanders). Vet Pathol (1999) 1.14
The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene (2012) 1.13
Minerals, phenolic compounds, and antioxidant capacity of citrus peel extract by hot water. J Food Sci (2008) 1.12
Transmission of human papillomavirus type 11 infection by desquamated cornified cells. Virology (2001) 1.12
Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res (1999) 1.12
Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene (1995) 1.12
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene (2006) 1.11
Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol (1996) 1.11
Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet (1986) 1.10
Analysis of the herpes simplex virus type 1 OriS sequence: mapping of functional domains. J Virol (1991) 1.10
Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res (2000) 1.10
Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience (2005) 1.10
Predictors of adopting leisure-time physical activity among a biracial community cohort. Am J Epidemiol (1995) 1.09
Association of herpesvirus with fibropapillomatosis of the green turtle Chelonia mydas and the loggerhead turtle Caretta caretta in Florida. Dis Aquat Organ (1999) 1.09
The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol (1993) 1.09
N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene (1995) 1.08